secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053949
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus signs $100M royalty financing with Ligand; $75M upfront for BOT/BAL and partner programs
--------------------------------------------------------------------------------

- Ligand pays $75M at closing for 18.75% of royalties and 31.875% of milestones on six partnered oncology programs, plus 2.625% royalty on BOT/BAL net sales.
- Ligand has option to invest additional $25M on same terms; Agenus may syndicate up to $125M more, bringing total potential to $200M.
- Warrant issued to Ligand for 867,052 shares of AGEN common stock at $17.30, exercisable until May 6, 2029.
- Funds will support BOT/BAL confirmatory Phase 3 trial in r/r MSS CRC liver metastases-negative and launch readiness activities.
- Covered programs include BMS-986442, AGEN2373 (Gilead), INCAGN2385/2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/0000950170-24-053949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/agen-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer